Related Experiment Video

Updated: Jul 11, 2026

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
07:59

A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes

Published on: March 25, 2014

Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for

L H Brinckerhoff1, V V Kalashnikov, L W Thompson

  • 1Department of Surgery, University of Virginia, Health Sciences Center, Charlottesville, VA, 22906, USA.

International Journal of Cancer
|September 25, 1999
PubMed

Insights

Tumor-reactive peptides like MART-1(27-35) are unstable in human plasma, degrading within hours. Modifications such as capping or PEGylation can enhance peptide stability and maintain immunogenicity for cancer vaccines.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Peptide epitopes targeting tumor-reactive cytotoxic T-lymphocytes (CTL) are crucial for cancer vaccine development.
  • The in vivo pharmacokinetics and pharmacodynamics of these immunogenic peptides remain poorly understood.
  • Tumor peptides are predicted to have short in vivo half-lives, limiting their therapeutic potential.

Purpose of the Study:

  • To assess the stability of the immunogenic peptide MART-1(27-35) in normal human plasma (NHP).
  • To identify modifications that protect MART-1(27-35) from enzymatic degradation without compromising immunogenicity.
  • To evaluate the impact of these modifications on peptide stability and CTL recognition in vitro.

Main Methods:

  • Incubation of MART-1(27-35) and its modified forms in NHP for varying durations.
  • Assessment of peptide stability by measuring the loss of CTL reactivity.
  • Evaluation of modified peptides for stability and recognition by MART-1(27-35)-reactive CTL.

Main Results:

  • The native MART-1(27-35) peptide exhibited rapid degradation in plasma, with a half-life of approximately 22 seconds.
  • Degradation was attributed to peptidase activity.
  • C-terminal amidation, N-terminal acetylation (peptide capping), and C-terminal PEGylation significantly enhanced peptide stability.
  • Modified peptides retained their ability to be recognized by CTL.

Conclusions:

  • The immunogenic peptide MART-1(27-35) is highly unstable in plasma, suggesting similar instability in vivo.
  • Modifications that enhance peptide stability, such as capping or PEGylation, are promising strategies to improve the efficacy of peptide-based cancer vaccines.
  • Stabilizing immunogenic peptides could enhance their therapeutic potential in cancer immunotherapy.

More Related Videos

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope08:09

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope

Published on: March 24, 2017

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Mitochondrial Precursor Proteins01:39

Mitochondrial Precursor Proteins

Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70  chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial precursors...
Translocation of Proteins into the Mitochondria01:19

Translocation of Proteins into the Mitochondria

Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...